1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Shine-On Biomedical Co., Ltd.

Shine-On Biomedical Co., Ltd.

TTPEX:6926
65.40
TWD
-0.10
(-0.15%)
3.17BMarket Cap
Shine-On Biomedical Co., Ltd.
TPEX:6926
(Taipei Exchange)

Recent

price

65.40

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
TTM
TWD
- -
- -
- -
- -
0.19
- -
0.6
- -
Revenue per Share
- -
- -
-0.46
-0.43
-0.75
-2.39
-2.21
- -
Basic EPS, GAAP
- -
- -
-0.5
-0.54
-0.55
-1.85
-2.33
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
18.22
23.57
22.82
20.43
18.22
15.89
Book Value per Share
- -
- -
18.2
23.5
22.75
20.36
18.04
15.71
Tangible Book Value per Share
50
43
18
45
50
50
50
50
Basic Weighted Avg Shares
- -
- -
- -
- -
10
- -
30
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
-658.16
- -
-418.33
- -
Operating Margin (%)
- -
- -
1
2
2
2
2
- -
Depreciation Expense
- -
- -
-8
-20
-37
-119
-110
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
-390.22
- -
-367.62
- -
Profit Margin (%)
- -
- -
904
1,166
1,130
1,012
892
776
Working Capital
- -
- -
2
1
- -
1
- -
- -
LT Debt
- -
- -
908
1,174
1,136
1,018
907
791
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
-1.86
-1.88
-3.22
-11.04
-11.46
- -
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
1
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
50
50
50
Market Capitalization
3,297
3,486
3,172

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
973
935
835
Cash, Cash Equivalents & STI
957
922
809
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
8
44
59
Payables & Accruals
- -
- -
- -
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-10.84%
Free Cash Flow
- -
- -
25.78%
Net Income, GAAP
- -
- -
-7.24%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
30
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-2.39
2025
- -
- -
-2.21
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Shine-On BioMedical Co., Ltd. (6926.TWO) researches, develops, and manufactures anti-cancer new drug products, focusing on antibody therapeutics and nucleic acid drugs delivered via exosomes. The company offers trispecific T cell engaging nanobody (SOA101), EphA10 trispecific antibody engaging immune cells (SOA201), iNb intrabody nanoscale intracellular specific antibody drug (SOA102), iNb STAR TriTE T cell receptor nanoscale trispecific antibody drug (SOA103); and nucleic acid drugs including exosome-carrying nucleic acid and chemotherapy drugs (SOB101). Founded in April 2021 by Dr. Chiu-Chin Huang and headquartered at 5/F-6, 633 Section 2, Taiwan Boulevard, Taichung, Taiwan, it listed on the Emerging Stock Market of the Taipei Exchange in November 2022 and employs 22 staff targeting oncology indications such as solid tumors, ovarian cancer, and glioblastoma primarily in Taiwan. Shine-On BioMedical leverages two patented platforms: Tri-Specific Antibody with T-cell Engager technology and Targeted Exosome for Drug Delivery, with SOA101 advancing to Phase 1/2 clinical trials for locally advanced malignant solid neoplasms and recruiting patients. Recently, the company licensed its patented exosome small-molecule drug loading technology to ESCO Aster; founder Chiu-Chin Huang received the New Academy Member honor from the Industrial Technology Research Institute's Industry Academy; and it continues preclinical development of SOB-101 and SOB-102 alongside pipeline expansion.